



DOCKET NO.: L0624.70001US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ya Fang Liu  
Serial No: 09/886,964  
Confirmation No: 6742  
Filed: June 21, 2001  
For: MLK INHIBITORS FOR TREATMENT OF NEUROLOGICAL DISORDERS  
  
Examiner: Harle, Jennifer I.  
Art Unit: 1654

---

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 7th day of July, 2005.

  
June Watson

---

Mail Stop AMENDMENT  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

07/13/2005 MBERHE 00000049 09886964

02 FC:1806 180.00 0P

913976.1

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

Serial No.: 09/886,964  
Conf. No.: 6742

- 3 -

Art Unit: 1654

An early and favorable action is hereby requested.

Respectfully submitted,  
*Ya Fang Liu, Applicant*

By: *John R. Van Amsterdam*  
John R. Van Amsterdam, Reg. No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: L0624.70001US00  
Date: July 7, 2005  
**x07/07/05x**



FORM PTO-1449/A and B (Modified) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO. 09/886,964	DOCKET NO.: L0624.70001US00		
				FILING DATE: June 21, 2001	CONFIRMATION NO.: 6742		
				APPLICANT: Ya Fang Liu			
				GROUP ART UNIT: 1654		EXAMINER: Harle, Jennifer I.	
Sheet	1	of	1				

#### U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	Press Release of Cephalon Corporation, "Cephalon and H. Lundbeck Announce Discontinuation of CEP-1347 Clinic Parkinson's Disease," Investor Relations - News Release, (05/11/05) Pgs. 1-2,	


EXAMINER:	DATE CONSIDERED:
-----------	------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office has waived the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications.]

Form PTO-1449

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**  
*(Use several sheets if necessary)*
Docket Number (Optional)  
YFLU-P02-001Application Number  
09/886964Applicant  
Ya Fang LiuGroup Art Unit  
1631Filing Date  
June 21, 2001**COPY****U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	6,060,247	5/00	Miller et al.			
AB	5,854,043	12/98	Johnson			
AC	5,840,509	11/98	Ni et al.			
AD	5,817,479	10/98	Au-Young et al.			
AE	5,741,808	4/21/98	Lewis et al.			
AF	5,621,100	4/15/97	Lewis et al.			
AG	5,621,101	4/15/97	Lewis et al.			

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
AH	WO 9918193	4/15/99	WIPO				

**OTHER DOCUMENTS***(Including Author, Title, Date, Pertinent Pages Etc.)*

AI	Anderson, A. J. et al. DNA Damage and Apoptosis in Alzheimer's Disease: Colocalization with c-Jun Immunoreactivity, Relationship to Brain Area, and Effect of Postmortem Delay. <i>J. Neurosci.</i> 16, 1710-1719 (1 March 1996).
AJ	Bossy-Wetzel, E. et al. Induction of Apoptosis by the Transcription Factor c-Jun. <i>EMBO J.</i> 16, 1695-1709 (1997).
AK	Chen, Y. et al. The Role of c-Jun N-Terminal Kinase (JNK) in Apoptosis Induced by Ultraviolet C and $\gamma$ Radiation. <i>J. Biol. Chem.</i> 271, 31929-31936 (13 December 1996).
AL	Cheung, N. S. et al. Kainate-induced apoptosis correlates with c-Jun activation in cultured cerebellar granule cells. <i>J Neurosci Res.</i> 52, 69-82 (1 April 1998).
AM	David, G. et al. Cloning of the SCA7 Gene Reveals a Highly Unstable CAG Repeat Expansion. <i>Nature Genetics</i> 17, 65-70 (September 1997).
AN	Davis, R. J. Human JNK3 Alpha 2 Protein Kinase (JNK3A2) mRNA. <i>GenBank</i> Accession No. U33819
AO	Davis, R. J. Human JNK3 Alpha 2 Protein Kinase (JNK3A2) mRNA. <i>GenBank</i> Accession No. U33820.
AP	Davis, R. J. MAPKs: New JNK Expands the Group. <i>TIBS</i> 19, 470-473 (November 1994).
AQ	Derijard, B. et al. JNK1: A Protein Kinase Stimulated by UV Light and Ha-Ras That Binds and Phosphorylates the c-Jun Activation Domain. <i>Cell</i> 76, 1025-1037 (25 March 1994).
AR	Dickens, M. et al. A Cytoplasmic Inhibitor of JNK Signal Transduction Pathway. <i>Science</i> 277, 693 (1 August 1997).

Form PTO-1449

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**  
(Use several sheets if necessary)

Docket Number (Optional)

YFLU-P02-001

Application Number

09/886964

Applicant

Ya Fang Liu

Filing Date

June 21, 2001

Group Art Unit

1631

	AS	Dorow, Donna S. et al. Complete Nucleotide Sequence, Expression, and Chromosomal Localization of Human Mixed-Lineage Kinase 2. <i>Eur. J. Biochem.</i> 234, 492-500 (1995).
	AT	Duyao, M. et al. Trinucleotide Repeat Length Instability and Age of Onset in Huntington's Disease. <i>Nature Genetics</i> 4, 387-392 (August 1993).
	AU	Eilers, A. et al. Role of the Jun Kinase Pathway in the Regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons. <i>J. Neurosci.</i> 18, 1713-1724 (1 March 1998).
	AV	Gallo, K. A. et al. Identification and Characteristics of SPRK, a Novel src-Homology 3 Domain-containing Proline-rich Kinase with Serine/Threonine Kinase Activity. <i>J. Biol. Chem.</i> 269, 15092-15100 (27 May 1994).
	AW	Goodenough et al. <i>Society for Neurological Abstracts</i> 23, 1387 (October 1997).
	AX	Gupta, S. et al. Selective Interaction of JNK Protein Kinase Isoforms with Transcription Factors. <i>EMBO J.</i> 15, 2760-2770 (1996).
	AY	Ham, J. et al. A c-Jun Dominant Negative Mutant Protects Sympathetic Neurons against Programmed Cell Death. <i>Neuron</i> 14, 927-939 (May 1995).
	AZ	Herdegen, T. et al. Lasting N-Terminal Phosphorylation of c-Jun and Activation of c-Jun N-Terminal Kinases after Neuronal Injury. <i>J. Neurosci.</i> 18, 5124-5135 (15 July 1998).
	BA	Hirai, S. et al. MST/MLK2, a Member of the Mixed Lineage Kinase Family, Directly Phosphorylates and Activates SEK1, an Activator of c-Jun N-terminal Kinase/Stress-activated Protein Kinase. <i>J. Biol. Chem.</i> 272, 15167-15173 (13 June 1997).
	BB	The Huntington's Disease Collaborative Research Group. A Novel Gene Containing a Trinucleotide Repeat that is Expanded and Unstable on Huntington's Disease Chromosomes. <i>Cell</i> 72, 971-983 (26 March 1993).
	BC	Kyriakis, J. M. et al. The Stress-Activated Protein Kinase Subfamily of c-Jun Kinases. <i>Nature</i> 369, 156-160 (12 May 1994).
	BD	Lin, A. et al. Identification of a Dual Specificity Kinase that Activates the Jun Kinases and p38-Mpk2. <i>Science</i> 268, 286-290 (14 April 1995).
	BE	Liu, Ya Fang. Expression of Polyglutamine-expanded Huntington Activates the SEK1-JNK Pathway and Induces Apoptosis in a Hippocampal Neuronal Cell Line. <i>J. Biol. Chem.</i> 273, 28873-77 (23 October 1997).
	BF	Liu, Ya Fang et al. Expression of the Huntington Mutant Activates JNK/SAPK and Induces Neuronal Apoptosis. <i>Society for Neurosci. Abstracts</i> 23, 1909 (25 October 1997) - ABSTRACT XP002115942.
	BG	Liu, Ya Fang et al. SH3 Domain-dependent Association of Huntington with Epidermal Growth Factor Receptor Signaling Complexes. <i>J. Biol. Chem.</i> 272, 8121-8124 (28 March 1997).
	BH	Liu, Z. et al. Dissection of TNF Receptor 1 Effector Functions: JNK Activation is Not Linked to Apoptosis While NF-KB Activation Prevents Cell Death. <i>Cell</i> 87, 565-576 (November 1996).
	BI	Maroney, Anna C. et al. Mononeuron Apoptosis is Blocked by CEP-1347 (KT 7515), a Novel Inhibitor of the JNK Signaling Pathway. <i>J. Neurosci.</i> 18, 104-111 (1 January 1998).

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)			Docket Number (Optional) YFLU-P02-001	Application Number 09/886964
			Applicant Ya Fang Liu	JUL 11 2005 U.S. PATENT & TRADEMARK OFFICE
			Filing Date June 21, 2001	
	BJ	Martin, J. H. et al. Developmental Expression in the Mouse Nervous System of the p46/p42 SAP Kinase. <i>Brain Res. Mol. Brain Res.</i> 35, 47-57 (January 1996) – ABSTRACT ONLY.		
	BK	Nagafuchi, S. et al. Structure and Expression of the Gene Responsible for the Triplet Repeat Disorder, Dentatorubral and Pallidoluysian Atrophy (DRPLA). <i>Nature Genetics</i> 8, 177-182 (October 1994).		
	BL	Nishina, H. et al. Stress Signaling Kinase Sek1 Protects Thymocytes from Apoptosis Mediated by CD95 and CD3. <i>Nature</i> 385, 350-357 (23 January 1997).		
	BM	Paulson, H. L. et al. Trinucleotide Repeats in Neurogenetic Disorders. <i>An. Rev. Neurosci.</i> 19, 79-107 (1996).		
	BN	Rana, A. et al. The Mixed Lineage Kinase SPRK Phosphorylates and Activates the Stress-activated Protein Kinase Activation SEK-1. <i>J. Biol. Chem.</i> 271, 19025-19028 (9 August 1996).		
	BO	Schwarzchild, M. A. et al. Glutamate, But Not Dopamine, Stimulates Stress-Activated Protein Kinase and AP-1 Mediated Transcription in Striatal Neurons. <i>J. Neurosci.</i> 17, 3455-3466 (15 May 1997).		
	BP	Snell, R. et al. Relationship Between Trinucleotide Repeat Expansion and Phenotypic Variation in Huntington's Disease. <i>Nature</i> 4, 393-397 (August 1993).		
	BQ	Thomas, L. B. et al. DNA End Labeling (TUNEL) in Huntington's Disease and other Neuropathological Conditions. <i>Exp. Neurol.</i> 133, 265-272 (June 1995) – ABSTRACT ONLY.		
	BR	Tibbles et al. MLK-3 activates the SAPK/JNK and p378/RK pathways via SEK1 and MKK3/6. <i>EMBO J.</i> 15, 7026-7035 (1996).		
	BS	Virdee, K. et al. Composition Between the Timing of JNK Activation, c-Jun Phosphorylation, and Onset of Death Commitment in Sympathetic Neurons. <i>J. Neurochem.</i> 69, 550-561 (1997).		
	BT	Yan et al. Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. <i>Nature</i> 372, 798-300 (December 1994).		
	BU	Yang, D. D. et al. Absence of Excitotoxicity-Induced Apoptosis in the Hippocampus of Mice Lacking the Jnk3 Gene. <i>Nature</i> 389, 865-870 (23 October 1997).		
	BV	Yardin, C. et al. FK506 antagonizes apoptosis and c-jun protein expression in neuronal cultures. <i>Neuroreport</i> 9, 2077-80 (22 June 1998).		
EXAMINER			DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.				